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Abstract
The purpose of this paper is to describe the updated biotechnologies approved to be
used for identifying precancerous cervical lesions in clinical practice. The paper focuses
on the new biotechnologies able to detect human papillomavirus (HPV) such as nucleic
acid hybridization assays, signal amplification assays, and nucleic acid amplification.
Particular attention is given to the discussion regarding the differences among the
biotechnologies used, such as Digene Hybrid Capture test using Hybrid Capture 2
technology and the Cervista HR-HPV assay. The scientific progress is emphasized by
new markers such as cycline p16INK4a, viral oncoproteins E6 and E7, high-risk (HR) HPV
genotyping, and dual test p16/Ki67. The results of the large ongoing studies conduct‐
ed worldwide highlight these markers’ capacity to disclose the differences between
transient and transforming HPV infection and mild abnormal cytologies which could
spontaneously regress or develop into cancer. Although both screening programs and
opportunistic  screening  concerning  cervical  cancer  are  used  worldwide,  major
geographic differences exist nowadays as regards the access to these programs. Finally,
to  achieve  the  objective  of  this  study,  the  recommendations  of  various  guidelines
available across Europe, United States, and Australia, as well as the diagnosis tests
accessible to women in low-resource countries are presented.
Keywords: Pap’s smear, HPV genotyping test, E6/E7 mRNA, p16INK4a, dual test
p16INK4/Ki67
1. Introduction
According to the data reported by GLOBOCAN 2012 (IARC), cervical cancer is included among
the leading causes of cancer worldwide. As regards the incidence of cervical cancer, GLOBO‐
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CAN report underlines that this type of cancer is the fourth most common cancer in women,
and the seventh overall. The estimated number of new cases for 2012 is 528,000 [1]. For the same
year, the registered number of deaths from cervical cancer was assessed at 266,000 cases. In
terms of cervical cancer incidence and death by this disease, there is a major difference between
the demographic regions of the world, strongly corresponding with the resource-setting level.
Mortality varies 18-fold between various world regions, with rates ranging from less than 2 per
100,000 (in Western Asia, Western Europe, and Australia/New Zealand) to more than 20 per
100,000 (in Melanesia (20.6), Middle Africa (22.2), and Eastern Africa (27.6)) as stated by the
GLOBOCAN 2012 report. A valuable consequence of the cervical cancer screening programs’
implementation is that the incidence of cervical cancer rate dropped to half or more than half
over the past 30 years, especially in countries with high levels of resources. For 2016, accord‐
ing to the American Cancer Society’s estimates for cervical cancer in the United States, approx‐
imately 12,990 new cases of invasive cervical cancer will be diagnosed and 4120 women will die
from cervical cancer. Cervical cancer is extremely rare in women younger than 20 and women
over 65 years of age; only 15% of cervical cancer was reported to be identified at these ages. The
improvement of collected data quality (statistics, information range) as concerns the occur‐
rence of cervical cancer and the death by this disease is due to the implementation of national
screening programs in many countries. Nowadays, more types of cervical cancer screening
programs are in place, and a larger number of different biotechnologies are available across the
world, which allow to identify early precancerous conditions of the cervix and therefore to
obviate progression to cancer. On the other hand, it is very important that clinicians know the
usable benefits and potential harms of biotechnologies able to achieve the triage of women with
abnormal cytology or to identify cases with high-risk human papilloma virus in the stage of
transforming infection. Due to a noteworthy scientific progress, clinicians now have many
possibilities for early detection of a cervical lesion that might evolve into cervical cancer. The
aim of the new biotechnology procedures is to achieve both high sensitivity and specificity in
order to differentiate cervical lesions that may develop into cancer from those which sponta‐
neously regress. Within the frame of this paper are included both the principal methods
recommended by clinicians and researchers in cervical cancer field and the benefits and
disadvantages of each biotechnology and marker. Our approach is designed so as to be useful
especially to gynecologists with a view to a better management of the diagnosis and treat‐
ment of precancerous lesions. Hence, this paper explains what attempts should be made in the
framework of each chosen biotechnology and what kind of tests increases the accuracy of an
early diagnosis with regard to precancerous cervical lesions.
The data collection was performed by literature search, using PubMed, EMBASE, and the
Cochrane Library (covering the 2000–2015 time frame), the main subject being detection of
Human Papillomavirus Infection and cellular markers for early detection of precancerous
cervical lesions. This study makes reference to the results of large studies published world‐
wide, such as in ATHENA, HERMES, PALMS, KPNC studies, Compass Trial, and the
Newsletter on Human Papillomavirus––HPV Today (2015). This paper is structured in three
sections. The first one covers different types of biotechnologies able to uncover precancerous
and cancerous cervical lesions which are approved for use in medical clinical practice. The
second section is dedicated to discussions about the benefits and drawbacks of each biotech‐
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nology reported to detect precancerous lesions. At last, attention is paid to recommendations
of the overall current guidelines.
2. Biotechnologies able to detect the precancerous and cancerous cervical
lesions
A strong contribution to the early detection of precancerous cervical lesions belongs to
Papanicolou. The Pap’s test has been in place since 1950, when George Papanicolou introduced
this method as a cytological test able to detect morphological changes of abnormal cells.
Generally, there are three kinds of markers for cervical cancer screening: viral markers, cellular
markers, and epigenetic markers, which can identify, alone or in combination, early precan‐
cerous cervical lesions.
The laboratory tests able to reveal precancerous and cancerous cervical lesions use cytololog‐
ical, viral, cellular, and genetic markers such as Pap’s test, HPV genotyping test, cellular
markers, epigenetic markers, and other markers.
2.1. Pap’s test: cytological diagnosis
Papanicolau stain––commonly known as Pap’s test––is the best-performing method used for
cervical screening. The cytologist analyses, via this test, the exfoliated cervical cells to detect
the morphological changes characteristic to neoplasic alterations. The cervical cell samples
must be taken within the squamocolumnar junction of the cervix. This area is relatively
accessible, making sampling easy, but it is unable to provide information about the lesions
within the endocervical canal such as adenocarcinoma precursors [2, 3]. For the same Papa‐
nicolou stain, there are two methods that differ in terms of collecting technology: one is used
to collect cervical cells (being known as conventional type), and the other is liquid-based
(cytology type).
The conventional type uses the fixation of cervical cells of the sample, followed by classic Pap
staining (EA 50, Hematoxilina Harris, Orange G, and different concentrations of ethanol). The
duration of this procedure is about 45 min.
The liquid-based collection medium biotechnology is deemed more advanced because it is
more versatile. Cervical cells are collected by using a cytobrush, which is then introduced into
a collection medium (e.g., Cytofast). This method gives the opportunity both to keep the
physiological structure and morphology of any kind of cells for 24 months at room temperature
and to perform more investigations (e.g., HPV oncotypes, cyclin immunomarkers) [4, 5]. Since
2013, Hospitex Diagnostics highlights that the monolayer slides from liquid-based collection
medium are safer, faster and fully representative, in comparison with the conventional smear
screening procedure. The interpretation of the cytological results is done according to the
Bethesda System Criteria established in 2001. During the past 15 years, a cytological diagnosis
which included medical recommendation was possible due to the Bethesda System Criteria.
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2.2. Viral markers
The viral markers validated for usage in cervical cancer detection are HPV DNA and HPV
genotyping, E6/E7 mRNA, and HPV proteins [6].
First of all, this paper describes, in line with its purpose, the biotechnologies which can be used
to become aware of human papillomavirus infection (HPV) and identify the high-risk HPV
genotypes (HR-HPV). There are several other technologies able to identify human papilloma‐
virus infection. These methods have different benefits and drawbacks, for which reason a good
option should be made to properly choose the individual test or screening program.
One of the following methods should be used to accomplish HPV detection: nucleic acid
hybridization assays, signal amplification assays, and nucleic acid amplification [7, 8].
The techniques able to employ radiolabeled nucleic acid hybridization assay to identify HPV
infection are Southern blotting, in situ hybridization, or dot blot hybridization.
Signal amplification assays pertain to another biotechnology consisting in two tests known as
the Digene Hybrid Capture test which utilizes Hybrid Capture 2 (hc2) technology (by Qiagen)
and the Cervista HR-HPV assay (by Hologic) [9].
Nucleic acid amplification methods involve many kinds of methodologies based on microar‐
ray analysis, PapilloCheck, polymerase chain reaction (PCR), real-time PCR, Abbott real-time
PCR, COBAS 4800 HPV test, HPV genome sequencing, the Linear Array, CLART human
papillomavirus, INNO-LiPA, clinical array HPV, Microplate colorimetric hybridization assay,
HPV-mRNA detection, HPV viral load quantification and integration.
Many technologies approved in the Unites States and Europe, relying on large population-
based studies and randomized trial, recommend using Hybrid Capture 2 test and Cervista test
to spot HPV infection. Hybrid Capture 2 test was endorsed by the US Food and Drug Admin‐
istration (FDA) in 2003 and is able to detect 13 HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, and 68) or 5 low risk (LR)-HPV types (6, 11, 42, 43, and 44), using specific antibodies’
signal amplification and chemoluminescent detection. In 2009, FDA approved the Cervista
HR-HPV, which detects 14 HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and
68) by using a signal amplification method and a fluorescent signal for detecting specific
nucleic acid sequences. In 2009, FDA approved another HPV DNA test, Cervista HPV 16/18,
which uncovers HPV 16 and 18 oncogenotypes [10].
In April 2014, FDA approved Cobas HPV test, which is a PCR-based HPV DNA test using the
same fluorescent label for the fluorescent signal from 12 HR-HPV and simultaneous recogni‐
tions with three separate fluorescent labels of HPV 16, HPV18, and beta-globulin signals.
When applied alone, the detection of HR-HPV DNA does not discriminate between the
transient and transforming HPV infections. This differentiation is possible by discerning viral
oncoproteins E6 and E7 mRNA and protein expression. The progression from a transient to a
transforming HPV infection is identified by the high increase of E6/E7 mRNA expression [11,
12]. These oncoproteins interfere with key cellular cycles that control cell proliferation and
apoptosis. E7 disrupts pRb from its binding to E2F, and E6 interferes with p53. Therefore, viral
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oncoprotein E7 triggers uncontrolled cell cycling and E6 abrogates apoptosis. Two of the most
widespread tests of the commercial assays designed to detect HPV E6/E7 mRNA are Pre Tect
Proofer (Norchip), which detects five oncotypes of HR-HPV (16, 18, 31, 33, and 45), and
APTIMA (GenoProbe) which covers 14 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66, and 68).
Another HPV assay––known as Qiagen assay (United States)––is an adoption of Digene HC2
assay. The signal amplification assay perceives 14 different HR-HPV oncotypes (16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, and 66). The particularity of Qiagen HPV assay consists in the fact
that this platform does not require electricity or water, but only needs a limited work space
(25 × 50 cm2). The result is obtained shortly (2.5 h only).
The main methods used to detect HPV integration are PCR, fluorescence in situ hybridization,
and Real-Time PCR. The latter two methods allow calculating the ratio between the levels of
E2 and E6/E7 HPV genes. When the HPV is integrated, the viral genome shows a 1:1 ratio
between the E2 and E6/E7 genes [13].
2.3. Cellular markers
The cell markers approved by the World Health Organization (WHO) to be used in clinical
practice are p16INK4a and dual test p16INK4a/Ki67. Another possible option arises from the
ongoing research about a new clinical cell marker concerning the detection of topoisomerase
2α, in cervical cytology slides.
2.3.1. Cellular markers: cyclin p16INK4a
Uncovering of p16INK4a is tightly correlated with HPV integration. In a normal cell, p16INK4a
blocks cyclin-dependent kinases (CDK) 4/6. Increased expression of the E6 and E7 oncogenes
disrupt cell cycle regulation. In the normal cell, cell cycle progression is activated by CDK 4/6
and partially regulated by p16INK4a. However, because in HPV-transformed cells, cell cycle
activation is caused by E7 and not by CDK 4/6, p16INK4a has no effect on the cell cycle activation.
Increased expression of p16INK4a in cells driven by viral oncogene-mediated cell cycle dysfunc‐
tion can be distinguished through cellular immunostaining by immunocytology or immuno‐
histology tests [14]. In brief, p16INK4a is a tumor-suppressor protein and cyclin-dependent
kinase (cdk) inhibitor that blocks CDK 4/6-mediated pRb phosphorylation to inhibit E2F-
dependent transcription and cell cycle progression. It is obvious that the progression of
dysplastic lesions to cancer is highlighted by increased expression of two viral oncogenes, E6
and E7. The last-mentioned oncoprotein, E7, inactivates retinoblastoma gene product (pRB)
that inhibits transcription of the cyclin-dependent kinase inhibitor gene p16INK4a. This explains
why the overexpression of p16INK4a is similar to the increased activity of E7, and so the
overexpression of both p16INK4a and E7 are markers of HPV integration in the genome of the
host cell [15]. The cyclin p16INK4a must be evaluated as a stand-alone test and as an adjunct to
cytology or HPV testing [16, 17].
The cervical cells are collected similar to those for Pap’s smear test. The liquid-based collection
medium has the advantage of being able to collect more cervical cells both for Pap’s smear,
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immunocytochemistry tests and for HPV genotyping test. In the current activity, the clinician
has the possibility to demand two tests used to identify specific immunocytomarkers, such as
p16INK4a alone or the dual test which evaluates, on the same cervical cell, two immunocyto‐
markers consisting in p16INK4a and Ki67.
Over the past 10 years, the cyclin inhibitor kinase p16INK4a has been identified by immunocy‐
tochemistry staining using a CINtec p16INK4a ready-to-use cytological kit (clone E6H4) manu‐
factured by mtm laboratories AG (Heidelberg, Germany). Wentzensen published the
morphological characteristics necessary to evaluate the immunocytological expressions of
p16INK4a within the cervical cell, both for nucleus and cytoplasm. Therefore, the criteria which
must be analyzed are increased nucleus size or increased nucleus/cytoplasmic ratio, irregular
nuclear shape, granular or hyperchromatic chromatin with variable cellular morphology,
together with the intensity of cytoplasmic staining [18].
There are many models in the published literature that allow identifying the intensity of the
immunocytoexpression of p16INK4a. One method used for a correct interpretation of the
immunoexpression classified samples as p16INK4a-negative and p16INK4a-positive when posi‐
tivity was observed for at least two of the aforementioned criteria. On the other hand, to obtain
greater accuracy in the slides’ interpretation, a scoring system was introduced, which scored
the absence and the gradual intensity of the immunocytological expression staining. Therefore,
the scoring system assigns 0 point for cases without p16-positive cells (p16−), 1 point for p16-
positive cells with changed morphology in the absence of nuclear abnormalities (p16+), 2 points
for p16-positive cells with a single nuclear abnormality (p16++), and 3 points for the presence
of at least two nuclear alterations within the same cell (p16+++) [18]. In this manner, the
physician can establish a correct cytodiagnosis much more accurately.
2.3.2. Cellular markers: p16INK4a/Ki67 dual-stained
The CINtec PLUS assay (mtm laboratories AG, Heidelberg, Germany) is currently gaining
increased credibility; it is a commercially available test which combines the immunostaining
of p16INK4a with the immunostaining of Ki67 within the same cervical cell [19].
This methodology allows the cytologist to see, within the same epithelial cell, the nucleus
stained red for Ki67 immunoexpression, and both the nucleus and the cytoplasm stained
brown for p16INK4a immunoexpression. The test has predictive power to identify the progres‐
sive evolution to a higher degree of dysplasia and cancer. Positive dual staining is significant
only for cells with modified morphology (atypical cells). Schmidt and other researchers [20]
highlight the fact that for a better cytological diagnosis, the most important aspect is the
positive dual staining within the nucleus of atypical cells. The evaluation of the p16/Ki67 dual
staining could be better ascertained by an automatic reader system that obviates subjectivism.
2.3.3. Other cellular markers
Other cellular markers expressed in the S-phase of uncontrolled cellular cycle due to the
activity of HPV oncoproteins in the stage of transforming infection include Topoisomerase 2α
(TOP2A) and minichromosome maintenance protein 2 (MCM2). These markers could be
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noticed in SurePath cervical cytology specimens by an indirect polymer-based immunoper‐
oxidase method (ProEx C, TriPath Oncology, Burlington, NC). The cytologist is interested in
evaluating the presence of nuclear stain in epithelial cells, and the combination of nuclear
staining and abnormal morphology. ProEx C is an immunocytochemical test, able to identify
the possibility of proliferative process in women with low-grade cytological abnormalities [21].
There are also many other studies that recommend the immunocytochemical test ProEx C for
TOP2A and MCM2 as adjunct test to conventional ASC-US cytology test.
2.4. Epigenetic markers
Nowadays there are ongoing studies about the chromosomal imbalances involved in the
development of cervical cancer. Researchers pay attention to the chromosomal changes
occurring early in the proliferative process. Epigenetic markers consist in DNA methylation,
chromosomal abnormalities, miRNA abnormalities, and proteomics. The literature data reveal
that it is about host methylation and viral methylation. Many genes are frequently methylated
and remain in a silent stage during carcinogenesis, acting as negative regulators of cellular cell
cycle. To identify the increased frequency of DNA, methylation of many genes (e.g., DAPK,
CADM1, TERT, CDH13, MAL) in the early stage of carcinogenesis may hint that these could
be biomarkers for early detection of cervical cancer [22]. Studies were not focused on a single
gene only, and therefore, a gene panel was developed (e.g., CADM/MAL; RAS ß/TWST/
MGMT), targeting to improve the possibilities to attain earlier the best triage of HPV-infected
cervical lesions. The analysis of viral methylation suggests that the promoter regions of
oncoprotein E5 and E7 are more frequently methylated in the later stages of carcinogenesis,
and as a consequence these tests allow to detect HGCIN [23].
Cervical cancer recognizes genomic instability manifested by amplification of the same
regions, especially 3q/TERC or loss of other regions such as 6q and 11q. These abnormalities
in the chromosomal architecture could be used in the triage of HPV-positive women with ASC-
US or LSIL conventional cytology [24]. Other biotechnologies including miRNAs with
increased or decreased expression, proteomics within cervical–vaginal mucus arise; their
target is to discover the best predictive markers to discover, at an early stage, the risk of
progress from mild to severe dysplasia and cancer.
3. Biotechnologies and test results: advantages and limitations
3.1. Pap’s test: advantages and limitations
Researchers agreed that the advantage of Pap’s test consists in its high specificity concerning
the detection of women who do not prove to be positive for cervical lesions. On the other hand,
Pap’s test is limited due to its low sensitivity in identifying women with dysplastic cervical
lesion prone to develop into cancer. The studies conducted on women of Europe and North
America showed that the sensitivity of the cytology in detecting CIN2+ lesions is only 53%,
while other studies reveal a modest sensitivity (60–70%) [25, 26].
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An advantage of Pap’s test consists in its use for both opportunistic cervical cancer screening
and national screening programs. The clinician must know that neither the changes in the
terminology of cytology by Bethesda reporting system, nor the novel techniques such as liquid-
based cytology do not prove more efficient in terms of the improvement of the sensitivity and
specificity of Pap’s test [27, 28]. On the contrary, Hospitex Diagnostics’ report (2013) highlights
that the monolayer slides from liquid-based collection medium are safer, faster, and fully
representative in comparison with conventional smears screening procedure. We must admit
that the introduction of liquid-based cytology has decreased the number of inadequate slides
and allowed to advocate a reflex testing for other viral or molecular markers [29].
A disadvantage of Pap’s test is the need to be interpreted by two or more specialists trained
in cytology for a more accurate cytologic diagnosis; thereby, the test implies subjectivity in the
evaluation of morphology cells [30]. Also, the costs of Pap’s test are not negligible by two
reasons, the first is the training cost of the specialist reader and the second is the fact that
screening based on cytology frequently needs repeated Pap’s test during the lifetime. Initially,
the Pap’s test was recommended at 1-year interval, and this is why Pap testing brings sub‐
stantial cost burden on the health system [31]. The method of cytological screening is able to
perceive the lesions that have a high risk of progression, but this prospect is limited by the fact
that when used alone, the method can distinguish neither atypical squamous cells of unde‐
termined significance (ASC-US) lesion, nor low-grade squamous intraepithelial (L-SIL) lesions
able to spontaneously go into remission against lesions able to progress. Statistical data have
shown that 10–15% cases with ASC-US and LSIL cytology develop CIN3 [32, 33].
3.2. HPV test: advantages and limitations
The disadvantages of Pap’s test justify why it is necessary to identify the HR-HPV types. With
this aim in mind, researchers are trying to define new marks in order to get more powerful
characterizations for cervical cancer prevention.
As regards the time necessary to achieve a result concerning HR-HPV assay, an advantage can
be seen in Qiagen platform which needs only 2.5 h, while Digene Hybrid Capture HR-HPV
testing needs about 6 h. Therefore, the former platform allows both diagnosis and treatment
in a single day.
The disadvantage of HR-HPV assay is that it exposes women to overtreatment, as, when
applied alone, HR-HPV assay does not reveal the difference between transient and transform‐
ing HPV infections. These features do not make it possible to differentiate women with
spontaneous remission of cervical lesions, from women with progressive cervical lesions that
develop into cervical cancer. Hence, this triage of women with remission or progress of cervical
lesion with HPV infection requires a larger number of investigations such as detection of E6
and E7 mRNA markers whose immunoexpression is a real proof of HPV integration in host
cells.
The inconveniences of the three techniques which use radiolabeled nucleic acid hybridization
assays to detect HPV infection consist in relatively large amounts of purified DNA, more time-
consuming procedures, and low sensitivity of the results of test [8].
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The Hybrid Capture 2 system has the added advantage of detecting 13 HR-HPV types and 5
LR-HPV types [34].
Cervista assay shows a high sensitivity and specificity to HPV 16/18 genotyping and 100%
sensitivity in the detection of CIN3 [35, 36].
A deep analysis of the published reviews underlines that Hybrid Capture 2 test and Cervista
HR-HPV have two limitations concerning both the lack of differentiation between single HPV
genotype infections and multiple concurrent HPV genotype infections, and the shortage of a
test in relation to quantitative viral load [10]. It is very important for the gynecologists to obtain
details about the existence of HPV infection with type 16 or 18, because these types allow for
a stratification of the risk with reference to the possibility of developing cervical cancer.
Thereby, the detection of HPV 16 or 18 has both the advantage of stratifying the oncologic risk
of HPV infection and of providing clinicians with information which is useful in managing the
precursors of cervical lesions, taking into account that in situations with persistent infections,
the risk of precancerous lesions’ progression to cancer is between 10 and 15% in cases with
HR-HPV 16/18, and below 3% for all other combined HR types [7].
Abreu and colleagues [7] put forward a concept aiming to classify the necessity of DNA HPV
testing. These authors concluded that there are six circumstances which require the test, as
follows:
a. triage of women with equivocal or low-grade cytological abnormalities
b. follow-up of women with abnormal screening results who are negative at colposcopy/
biopsy
c. prediction of the therapeutic outcome after treatment of cervical intraepithelial neoplasia
(CIN)––management of follow-up
d. primary screening for HPV DNA testing, alone or in combination with a Pap’s test,
envisaging to detect cervical cancer precursors
e. gain valuable information on the persistence of certain HPV types
f. investigations of regional and country-based prevalence of type-specific HPV to provide
the baseline values against which the global impact of HPV vaccination can be assessed
in the future [7].
3.3. Cellular markers: advantages and limitations
3.3.1. Cycline p16INK4a
The p16INK4a positivity shows that the cervical cells are HPV-infected but could not clearly
detect a real progress to cancer. The p16INK4a positivity is correlated with HPV infection but
could not allow to discriminate between a HR-HPV or a LR-HPV oncotype infection. On the
other hand, the p16INK4a expression is independent of the HPV type, and therefore genotyping
is unnecessary. In the context of disruption of cell cycle regulation, the p16INK4a expression by
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cycling cells is a specific marker of HPV-E7 overexpression or other events that inactivate Rb
[15].
The immunoexpression of p16INK4a exists both in the nucleus and cytoplasm, but its intensity
is in line with the degree of cervical dysplasia. Only the p16INK4a overexpression within the
nucleus of the cell shows a high degree of cervical dysplasia. The presence of low p16INK4a
immunoexpression within the cytoplasm could not be related to cervical dysplasia’s progress
to cancer. Another limitation of this marker is the subjectivism in immunostaining slides’
evaluation, despite the above-mentioned criteria and the scoring system proposed by Went‐
zensen, Samarawardana, and Denton. The evaluation of slides requires special cytologist
abilities to detect the morphological abnormalities of cells and interpret the immunoexpression
degree p16INK4a. The clinician must take into account the possibility that sometimes the
cytologist notices the physiological presence of p16INK4a. In this context, it is necessary to require
a morphological evaluation of p16-immunostained cells with the purpose of distinguishing
HPV-transformed cells from metaplastic cells [37, 38].
Along with the aforementioned features of cycline p16INK4a, and with the benefits and draw‐
backs of this test, the conclusion is that it must be evaluated both as a stand-alone test and as
an adjunct to cytology or HPV testing. In line with the overall opinion, cyclin p16INK4a is a
specific biomarker able to identify dysplastic cervical epithelia in sections of cervical biopsy
samples or cervical smears [34]. The meta-analysis of reviews published shows that there is a
major heterogeneity in the methods used to identify p16INK4a in samples. As regards the
statistical value in detecting CIN2+ lesions, cycline p16INK4a has a sensitivity between 0.59 and
0.96, and a specificity flanked by 0.41–0.96 [17].
3.3.2. Dual test p16INK4a/Ki67: advantages and limitations
Dual test p16INK4a/Ki67 has a better interobserver reproducibility and accuracy in cervical
cancer screening compared to stand-alone p16INK4a. As indicated in Kaise Permanente Northern
California (KPCN) study, where cancer screening was performed based on HPV and cytology
co-testing by p16/Ki67 dual staining in 2400 HPV-positive women, the recommendation to use
p16/Ki67 cytologies is feasible in routine cytology laboratories with minimal time of training
and easy reproducibility [39, 40].
The evaluation of p16/Ki67 dual staining could be better conducted by an automatic reader
system that reduces subjectivism to the highest possible extent.
p16INK4a/Ki67 dual test has a higher sensitivity than Pap’s test in identifying high-grade cervical
lesions associated with HR-HPV infection and the same specificity as the above-mentioned
test.
3.4. Epigenetic markers: advantages and limitations
Despite some extended studies investigating the utility of epigenetic markers, such markers
are not yet applied in clinical practice and guidelines do not refer to samples of these biotech‐
nologies. However, the researchers’ discoveries as regards this solution proved the utility of
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epigenetic markers for the triage of HPV-positive women with mild abnormal cytologies.
There seems to be an opportunity in the future to self-sample from cervical mucus or vaginal
fluid, and such samples could theoretically be investigated with reference to epigenetic
markers.
4. Discussion: recommendations of the large studies and worldwide
guidelines
Pap’s test has limited sensitivity to detect precancerous cervical lesions but has high specificity.
Compared to cytological diagnosis by HPV DNA testing, it offers a higher sensitivity and a
long-term reassurance as regards the minimal risk of developing cervical cancer in women
who were proven to be negative in HPV-DNA testing. Hence, these women are safe as regard
a progressive dysplasia and could benefit from a large interval between cytological tests, with
extension to 2–3 years of the screening interval [29].
In keeping with the ASC-US/LSIL Triage Study (ALTS)––1998, HPV DNA testing is a viable
strategy able to clarify especially ASC-US cytology. In fact, ALTS Study counsels clinicians to
manage ASC-US cytologies using three different options: triage by HPV testing as an adjunct
to cytology, immediate referral to colposcopy, and conservative management with repeating
Pap’s test. The triage of ASC-US cytologies has relevant significance, because approximately
10–15% of women with ASC-US cytologies proved to be CIN3 at histopathological exam. The
relevance of ALTS study consists in the fact that researchers deem that HPV DNA testing could
be achieved only by triage of ASC-US cytologies, while the triage of mildly abnormal cytologies
is not possible due to the high number of HR-HPV belonging to this female population [32].
Numerous studies have confirmed that HPV testing demonstrates high sensitivity and lower
specificity for detecting high-grade cervical intraepithelial lesions. This poor specificity is
explained by the fact that most HPV infections are transient and only a lower number of cases
develop transforming infections.
Due to the fact that HPV DNA testing offers higher sensitivity and Pap’s testing has higher
specificity, researchers have progressed in line with the necessity of developing a new marker
able to corroborate high sensitivity and specificity.
Berjeron and colleagues (2010) demonstrated on 500 cases, by using H&E-stained slides, as
well as p16INK4a-immunostained slides analyzed by the same 12 pathologists, that the diagnosis
was improved and the sensitivity increased by about 13% after adding p16INK4a immunostain‐
ing. The research results recommend using p16INK4a for clinical practice, because this marker
was proved able to identify both CIN1 lesions associated with HR-HPV types and CIN2+
lesions [41].
The papers published in 2010 by Samarawardana and Denton have shown that p16INK4a
immunostaining on cytology provides significantly better specificity than HR-HPV for the
triage of ASC-US and LSIL cytology cases [42, 43].
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In conclusion, the diagnosis accuracy is higher when clinicians suggest one of these options:
HPV DNA testing in conjunction with Pap’s test or p16INK4a associated with Pap’s test for the
triage of ASC-US cytologies.
In 2014, ATHENA study results demonstrated that COBAS HPV technology contributes to the
ASC-US triage. The researchers’ remarks were useful for a new approach of the cervical cancer
screening. Hence, ATHENA study highlights the fact that negative intraepithelial lesions
(NIEL) on cytological exam proved to be ≥CIN3 on histopathological exam. The careful data
analysis of ATHENA study has shown that more than 57% of women aged 25–29 years whose
cytological diagnosis is negative for intraepithelial cervical lesion proved to have a histopa‐
thological diagnosis ≥ CIN3. This evidence justifies why HR-HPV testing for genotypes 16/18
is more efficient in the primary screening of the cervical cancer compared to the Papanicolou
cytology test. Cervical lesions able to progress to cancer could be prevented by the early
detection of 16 and 18 HPV genotypes by COBAS HPV technology [44]. This technology is able
to simultaneously identify 16 and 18 HPV genotypes (the HPV types that are the most
responsible for the progress of dysplastic cervical lesions) associated with other 12 oncogeno‐
types.
The major contribution of COBAS HPV technology consists in the information that individu‐
alization of the 16 or 18 HPV oncoproteins underlines the necessity to change the management
of an abnormal middle dysplasia from follow-up strategy with Pap’s test repeated in 1 year,
to other strategies involving, for example, colposcopy, biopsies.
However, HR-HPV testing alone is not able to distinguish between transient and proliferative
HPV infections. In view of the gains and weaknesses proven by research as regards the
usefulness of Pap’s test and HR-HPV in screening women in order to discover those cervical
lesions able to evolve into cancer, it is obvious that attention should also be paid to other
biomarkers for increased credibility. Therefore, the progress of research led to the necessity of
highlighting an immunomarker capable to increase the sensitivity of Pap’s test. The cyclin
p16INK4a, both in cytology exam and histology exam, is able to identify the HPV-infected cells
and therefore to provide a more accurate diagnosis. As a matter of fact, it is acknowledged that
the positivity of p16INK4a is an important feature of high-risk HPV infected cells.
Women tested HPV DNA-positive and with p16INK4a ICC-negative could be safely managed
with follow-up HPV DNA testing in 2 to 3 years.
Conversely, the positivity for Ki67 in the cell nucleus is a marker of nuclear proliferation. The
intensity of Ki67 immunoexpression increases more strongly in abnormal cells. The advantage
of p16INK4a test used alone or within a dual test (p16INK4a and Ki67) is that the high intensity of
p16INK4a and Ki67 immunoexpression in the nucleus warns that the cell will develop into cancer.
If p16INK4a is positive in the cytoplasm only, there is a transient HPV infection, and the cervical
lesion is able to spontaneously regress.
As regards the significance of p16INK4a/ Ki67 dual staining immunohistochemical test, Samar‐
awardana and colleagues showed as early as 2011 that this test has increased its capacity to
identify high-grade cervical lesions [45].
Human Papillomavirus - Research in a Global Perspective98
The novel data established that the p16INK4a/ Ki67 dual staining by immunocytochemical (ICC)
method is a better solution to identify the high-grade cervical lesions associated with HR-HPV
infection [46].
Another aspect which must be thoroughly discussed consists in the careful measurement of
the sensitivity and specificity of each biotechnology used for the diagnosis of cervical lesions
[43].
A meta-analysis performed by Jolien Roelens (2012) highlights that p16INK4a ICC has more
accuracy than the HR-HPV test concerning the triage of ASC-US cytology samples. Both tests
have similar sensitivities, but p16INK4a ICC has higher specificity than HR-HPV test. In LSIL
samples, p16INK4a was more specific, but less sensitive than HR-HPV in the detection of ≥CIN2+
[20]. Over the past 10 years, similar results have been published by well-known researchers
such as Izaaks, Denton, Holladay, Wentzensen [14, 43, 48, 49].
The positive p16INK4a ICC test rises Pap’s test sensitivity to identify the cervical lesions prone
to develop into cervical cancer. Therefore, the intensity of p16INK4a immunoexpression in the
nucleus is in relation to the degree of cervical lesion.
In the study conducted by Denton and Bergeron (2010), it was shown that p16INK4a cytology
provides significantly better specificity than HR-HPV for the triage of ASC-US and LSIL. Both
HPV-testing and p16INK4a immunocytomarker test have similar sensitivity percentage rates,
capable to detect high-grade cervical lesions at histopathological exam. In conclusion, the
specialists involved in this research field have shown that p16INK4a cytology has the potential
of being used as a triage of abnormal cytology LSIL [43].
Beginning with 2010, Samarawardana et al. have demonstrated by statistical analysis that the
sensitivity (Se) and specificity (Sp) of p16INK4a for the detection of underlying CIN ≥ 2+ are 81.7%
and 83.3%, respectively (p = 0.81). They underline that the Se and Sp of HR-HPV are lower than
those of p16INK4a, albeit statistically significant: 78.1% and 50.9%, respectively (p < 0.01) [42].
There are many research studies recommending the usage of p16INK4a as a supplemental triage
biomarker for ASC-US and LSIL cytologies, which have already been assigned as “high-risk”
after HR-HPV detection [49, 50].
Large studies approached the comparison between the sensitivity and specificity of immuno‐
cytomarker p16 INK4a /Ki67dual stain versus HPV test in order to reveal if one of these tests is
statistically more powerful to detect high-grade histopathological lesions ≥CIN2+. So, PALMS
study is a bulky study which has enrolled 27,349 women from five European countries. All
women aged 18 and older were tested by conventional cytology and p16/Ki67 dual test, while
women aged 30 or older were tested by HPV DNA. The comparison between Se of p16INK4a /
Ki67 dual stain cytology versus Pap’s test with regard to the detection of high-grade cervical
intraepithelial neoplasia (HGCIN) has shown higher values for p16INK4a /Ki67 test (86.7 vs
68.5%). As regards the Sp of the tests, it was comparable (95.2 vs 95.4%). By comparing Se and
Sp of HPV DNA test versus p16INK4a /Ki67 dual stain, the study remarks that HPV DNA test
has a higher Se to detect CIN2+, 93.3 versus 84.7%, but a low drop in specificity, 93.0 versus
96%. On the other hand, the dual test p16/Ki67 sets the idea that the test offers the same high
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sensitivity and specificity to identify HGCIN (see Table 1). The conclusions of researchers
published on August 2015 within the Specialist Forum concerning PALMS study underline
that the immunoexpression of dual-stained p16/Ki67 biomarkers is a novel approach to
scrutinize efficiently for HGCIN and to achieve the same specificity conferred by Pap’s test.
Detection of HGCIN p16/Ki67 Pap’s test
Se Sp Se Sp
p16/Ki67 dual test versus Pap’s test 86.7% 95.2% 68.5% 95.4%
Detection of HGCIN p16/Ki67 HPV DNA test
Se Sp Se Sp
p16INK4a /Ki67 vs. HPV DNA 84.7% 96% 93.3% 93.00%
p16INK4a/Ki67 = dual test CINTech Plus; Se = sensitivity; Sp = specificity; HGCIN = high-grade cervical intraepithelial
neoplasia.
Table 1. Cellular markers able to detect HGCIN sensitivity and specificity––results of PALMS study.
Similar attention is given to the cervical cancer screening of vaccinated women. In this regard,
the trial known as Compass Trial is being conducted today in Australia. This trial enrolled
121,000 HPV-vaccinated women who are analyzed from the point of view of cervical screening
programs using HPV test versus cytology tests [52].
Methods Unites States Europe Australia
HPV vaccine NSP NSP
HPV DNA testing NSP primary test GR-triage NSP primary test
Co-test PAP NSP NO NSP
Pap’s test Conjunction to HPV DNA testing NSP
P16 GR––Triage GR––Triage GR––Triage
P16/Ki67 GR––Triage GR––Triage GR––Triage
E6/E7 mRNA GR––Triage GR––Triage GR––Triage
NSP = National Screening Programme; GR––Triage = Guideline Recommendations––Triage; NO = negative.
Table 2. Cervical cancer screening programmes and guideline recommendations––update.
In line with the recent discoveries made by researches and the large studies mentioned above,
the guidelines approved in the United States recommend HPV vaccination, HPV primary
screening and co-testing with Pap’s test, with major benefits in terms of sorting abnormally
low cytologies and extending the screening interval. The ATHENA study prescribes the
circumstances for applying the HPV test: triage of ASC-US in women over 21 years of age,
HPV test with reflex Pap’s cytology in women between 25 and 65 years, and HPV test with
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HPV 16/18 genotyping for primary screening in women older than 25. As to the accepted
screening interval, this is 3–5 years for women negative at both intraepithelial malign cervical
lesions (NIEML) and HPV infection, and 12 months in cases with HPV-positive test, but
cytology-negative for NIEML, followed up by classic advices when the tests are constantly
changed. Positive test for HPV 16/18 genotyping push the screening directly to colposcopy
due to the presence of an absolute risk for CIN3+ progression. The interval for screening is
prolonged to 5 years when women are negative at co-testing. Access to this screening program
is given only to women with healthcare insurance [53]. The present guideline recommenda‐
tions and cervical cancer screening programs existing nowadays are summarized in Table 2.
In Europe, there are many differences as regards the modality of carrying out the screening of
cervical cancer, because health policies and financial resources differ among Europe’s demo‐
graphic regions. The most commonly used national screening program is mainly Pap’s test;
however, it is complemented by other new markers and biotechnologies prescribed by
physicians with the goal of increasing diagnosis accuracy.
The Australian National Screening Program recommends only the screening using HPV test,
and encompasses ages between 25 and 74 (applicable if women were screened in the past). The
program includes both vaccinated and unvaccinated women. If the HPV test is positive, the
follow-up program will be in line with cervical screening pathway [52].
5. Conclusions
The detection of carcinogenetic HPV DNA, and especially of HPV 16/18 genotyping, stands
for approved tests to be used as primary screening and for triage of equivocal cytology equally
on vaccinated and unvaccinated women.
Recognition of E6/E7 mRNA is largely applied in adjunct to primary HPV screening to select
cases with HPV integrated in the host cell. The result of E6/E7 mRNA is able to achieve the
triage of equivocal or mildly abnormal cytology.
Uncovering of HPV protein by cytology and histology immunostaining underlines the
accuracy of diagnosis and can be used together with primary HPV screening or for the triage
of equivocal or mildly abnormal cytology.
The success that was achieved in researches across the world showed that the identification of
immnuocytomarkers inside the same cervical cell––dual stain p16INK4a and Ki67––warns more
accurately about the possibility of progression to cervical cancer.
Correctly performed and interpreted, the results of approved tests for cervical screening
programs allow to obtain an extended interval screening between 2 and 5 years, with a larger
number of advantages in terms of diagnosis accuracy and healthcare costs.
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